文献速递神经肿瘤小儿神经外科与脑积水

儿童高级别胶质瘤疫苗治疗:现状、挑战与未来方向

Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions.
PubMed 文献 · J Neurooncol · 2026-01-08

本文综述儿童高级别胶质瘤(pHGG)疫苗免疫治疗的科学依据、关键靶点(胶质瘤相关抗原、驱动突变新抗原、病毒抗原)及现有疫苗平台(肽疫苗、树突状细胞疫苗、mRNA疫苗、新抗原个性化方案),指出早期临床试验显示安全性与免疫原性,但中枢神经系统免疫环境、瘤内异质性、低突变负荷、免疫抑制微环境、激素使用及生产试验设计等挑战阻碍临床转化,未来需优化抗原选择、联合治疗、新型递送系统及儿童特异性免疫分析。

要点

  • pHGG疫苗靶点包括EphA2、IL-13Rα2、survivin、H3.3K27M、TP53、IDH1及CMV pp65。
  • 肽、树突状细胞、mRNA及新抗原个性化疫苗早期试验显示安全性和免疫原性。
  • 中枢免疫环境、异质性、低突变负荷、激素使用等限制疫苗临床转化。

核心结论

  • 疫苗疗法可能成为pHGG儿童治疗武器库的有意义补充,需持续多学科合作。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 早期临床试验结果证明疫苗平台安全且具有免疫原性。
  • 多种挑战阻碍临床转化,包括中枢神经系统免疫环境、瘤内异质性、低突变负荷、免疫抑制微环境、激素使用及生产试验设计障碍。

关键数值与推荐

  • 关键靶点包括胶质瘤相关抗原EphA2、IL-13Rα2、survivin,驱动突变新抗原H3.3K27M、TP53、IDH1,以及病毒抗原CMV pp65。
  • 疫苗平台包括肽疫苗、树突状细胞疫苗、mRNA疫苗和新抗原个性化方案。

临床怎么用

  • 未来需通过优化抗原选择、联合治疗、新型递送系统和儿童特异性免疫分析来克服障碍。

局限性

  • 中枢神经系统独特免疫环境、瘤内异质性、低突变负荷、免疫抑制微环境、激素使用及疫苗生产与试验设计的后勤障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric high-grade gliomas (pHGG) are among the most aggressive childhood brain tumors, with limited treatment options and poor prognosis. Vaccine-based immunotherapy offers a promising strategy by leveraging tumor-specific or associated antigens to stimulate durable anti-tumor immune responses with minimal toxicity. DISCUSSION: This review outlines the scientific rationale for vaccine therapies in pHGG, detailing key targets such as glioma-associated antigens (EphA2, IL-13Rα2, survivin), driver mutation–derived neoantigens (H3.3K27M, TP53, IDH1), and viral antigens (CMV pp65). We evaluate current vaccine platforms, including peptide vaccines, dendritic cell vaccines, mRNA-based vaccines, and neoantigen-personalized approaches, highlighting early-phase clinical trial results that demonstrate safety and immunogenicity. Despite encouraging preliminary data, several challenges hinder clinical translation, including the distinct immune environment in the central nervous system, intratumoral heterogeneity, low mutational burden, immunosuppressive microenvironments, steroid use, and logistical hurdles in vaccine production and trial design. Future research must address these barriers through optimized antigen selection, combinatorial therapies, novel delivery systems, and pediatric-specific immune profiling. CONCLUSION: With continued multidisciplinary collaboration, vaccine therapies may emerge as a meaningful addition to the therapeutic arsenal for children with pHGG.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Harper SD, Alderete JA, Baisiwala S, et al. Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions. J Neurooncol. 2026. PMID: 41504830. doi:10.1007/s11060-025-05403-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。